Newsfile Corp
11 Aug 2026, 12:44 UTC · 6w ago
Verdict
Headline takes no side. We score NTHI +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 75% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
NeOnc Technologies (NTHI) will release topline Phase 2a results for its NEO100 therapy in recurrent IDH1-mutant high-grade glioma on August 12 at 8:30 a.m. ET.
More positive than 99% of claims this week
The stock currently features a combination of a low float and elevated short interest.
So whatThese technical conditions can amplify upward price movements (short squeeze) if the upcoming clinical data is positive.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 78% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
The company is positioned for a 'high impact catalyst day' with upcoming Phase 2a clinical results and a favorable technical setup.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
9h ago
−5.4%
Price is moving against the score
$3.31 vs $3.50 close before publication (Aug 10) · not market-adjusted
NTHI chart →
